Chronic granulomatous disease and McLeod syndrome: Stem cell transplant and transfusion support in a 2-year-old patient-a case report

Front Immunol. 2022 Aug 23:13:994321. doi: 10.3389/fimmu.2022.994321. eCollection 2022.

Abstract

Chronic granulomatous disease (CGD) with McLeod neuroacanthocytosis syndrome (MLS) is a contiguous gene deletion disorder characterized by defective phagocytic function and decreased Kell antigen expression. CGD cure is achieved through hematopoietic stem cell transplant (HSCT) usually in the peri-pubescent years. The presence of MLS makes peri-transfusion support complex, however. Herein, we present the youngest known case of HSCT for CGD in the setting of MLS. A 2-year-old male patient was diagnosed with CGD plus MLS. Due to the severity of the child's systemic fungal infection at diagnosis, HSCT was deemed the best treatment option despite his small size and age. A related, matched donor was available, and a unique red blood cell support plan had been implemented. Reduced-intensity conditioning was used to reduce the transplant-related mortality risk associated with myeloablative protocols. The transplant course was uneventful; autologous red blood cell (RBC) transfusion support was successful and allowed for the avoidance of possible antibody formation if allogeneic units had been used. The patient achieved 1-year relapse-free survival. The developed protocols provide a viable path to transplant in the very young, and early transplant to cure could reduce disease-related morbidity.

Keywords: McLeod; allogeneic stem cell transplant; case report; chronic granulomatous disease; pediatrics; transfusion.

Publication types

  • Case Reports

MeSH terms

  • Child
  • Child, Preschool
  • Granulomatous Disease, Chronic* / genetics
  • Granulomatous Disease, Chronic* / therapy
  • Hematopoietic Stem Cell Transplantation* / methods
  • Humans
  • Male
  • Neuroacanthocytosis*
  • Treatment Outcome

Supplementary concepts

  • Neuroacanthocytosis, Mcleod Type